What Is Hormone Replacement Therapy? How Colombia Makes Optimization More Accessible

Roughly 70-80% of women experience menopausal symptoms severe enough to warrant medical attention, yet only 40-60% ever pursue treatment (NAMS, 2022). That gap between suffering and solution sits at the center of a conversation millions of women avoid having with their physicians. Hormone replacement therapy, often shortened to HRT, remains one of the most studied and misunderstood interventions in women’s health.

What Hormone Replacement Therapy Actually Does

Hormone replacement therapy restores hormonal balance by replacing hormones the body no longer produces in sufficient quantities, particularly estrogen and progesterone during the menopausal transition (The Menopause Society, 2022). As ovarian function declines, estrogen deficiency triggers a cascade of physical changes that extend well past reproductive health. Hormone therapy is most commonly used for menopausal symptom relief, addressing hot flashes, night sweats, and vaginal dryness that disrupt sleep, work, and daily comfort (The Menopause Society, 2022).

Menopause symptoms vary in severity, but moderate-to-severe vasomotor symptoms, meaning hot flashes and night sweats intense enough to interfere with functioning, typically signal a genuine need for systemic therapy rather than lifestyle adjustments alone (North American Menopause Society [NAMS], 2022). Systemic estrogen remains the most effective treatment available for these vasomotor symptoms, according to the 2022 NAMS position statement, which reviewed decades of clinical evidence (NAMS, 2022). Quality of life during this transition can decline sharply; researchers have compared the psychological burden of severe menopausal symptoms to that experienced by individuals facing insecure housing, underscoring how disruptive untreated symptoms become (NAMS, 2022).

Systemic Therapy Versus Local Estrogen Therapy

Systemic therapy delivers hormones through pills, skin patches, gels, or a vaginal ring designed to circulate estrogen throughout the bloodstream, addressing hot flashes, night sweats, and bone loss simultaneously (NAMS, 2022). Local estrogen therapy, delivered through a vaginal cream, tablet, or ring at low doses, targets vaginal symptoms and vaginal dryness specifically without the broader systemic exposure (NAMS, 2022). Women dealing exclusively with vaginal symptoms often find low-dose vaginal estrogen sufficient, while those managing severe hot flashes typically need systemic hormone therapy for meaningful relief.

Types of Hormone Therapy and How They Differ

Choosing between estrogen-only therapy, combined hormone therapy, and other formulations depends heavily on whether a woman still has a uterus. Estrogen therapy alone suits women without a uterus following hysterectomy, since estrogen replacement therapy without opposing progesterone can raise endometrial (uterine) cancer risk in women who retain their uterus (NAMS, 2022; Stuenkel et al., 2015). Combination therapy, which pairs estrogen with oral progesterone, protects the uterine lining and reduces that specific cancer risk while still relieving hot flashes and vaginal dryness (NAMS, 2022; American College of Obstetricians and Gynecologists [ACOG], 2014).

Combined hormone therapy comes in two structures worth understanding. Cyclic therapy mimics a natural menstrual cycle, producing scheduled menstrual periods, while continuous combined therapy delivers steady daily doses without a monthly bleed (NAMS, 2022). Bioidentical hormones, which are structurally identical to the hormones estrogen and progesterone naturally produced by the body, are available in FDA-approved hormone therapy formulations and prescribed under a health care professional’s prescription (NAMS, 2022; Stuenkel et al., 2015). Doctor-allies commonly individualize prescriptions using estradiol, progesterone, and DHEA based on baseline hormone levels drawn at the initial visit, since each hormone plays a distinct physiological role: estradiol supports bone density, collagen, and mood; progesterone balances estrogen and supports sleep and cholesterol regulation; and DHEA, produced by the adrenal glands, contributes to estrogen synthesis and naturally declines with age (Stuenkel et al., 2015). Symptom resolution under a personalized plan is rarely immediate; clients typically require several months of dosage adjustment across topical creams, vaginal inserts, or oral tablets before finding the formulation that fits their physiology, following ongoing physician-guided reassessment (NAMS, 2022).

Compounded hormone therapy and compounded drugs, by contrast, are custom-mixed by pharmacies and lack the same regulatory oversight; the Menopause Society has flagged compounded hormones for inconsistent dosing, contamination risk, and absent safety labeling (The Menopause Society, 2022). The Endocrine Society’s clinical practice guideline similarly notes insufficient evidence to support compounded bioidentical hormones over FDA-approved hormone therapy, given the absence of standardized quality testing (Stuenkel et al., 2015). ACOG’s 2014 Practice Bulletin reinforces this position, stating that data do not currently support compounded bioidentical hormones as a preferred option over regulated formulations (ACOG, 2014).

Delivery Methods Worth Knowing

Skin patches and other transdermal routes bypass the liver during initial processing, which matters enormously for safety. Transdermal estrogen carries a lower risk of blood clots than oral estrogen because it avoids the liver’s first-pass metabolism, a mechanism confirmed across multiple observational studies referenced in both the NAMS position statement and the Endocrine Society guideline (NAMS, 2022; Stuenkel et al., 2015). ACOG’s Practice Bulletin echoes this finding, noting that transdermal estrogen may carry a reduced risk for venous thromboembolism (blood clots) compared with oral administration (ACOG, 2014). The Endocrine Society specifically recommends transdermal delivery, whether by patch, gel, or spray, for women requesting hormone therapy who carry an elevated baseline risk of blood clots (Stuenkel et al., 2015).

Pellet therapy, inserted under the skin, offers another delivery option alongside topical creams, vaginal inserts, and oral tablets, though NAMS notes it lacks the same volume of long-term safety data as patches, gels, or oral tablets (NAMS, 2022). Response to any single delivery method varies from woman to woman, which is why doctor-allies track baseline hormone levels and adjust formulation type rather than dosage alone during the initial months of treatment. Oral progesterone remains standard for uterine protection in combined regimens, typically taken alongside systemic estrogen delivered through pills, patches, or the vaginal ring (NAMS, 2022; Stuenkel et al., 2015).

Benefits That Go Past Symptom Relief

Hormone therapy reduces vasomotor symptoms by roughly 85%, making it the most effective intervention for hot flashes and night sweats currently available (NAMS, 2022; ACOG, 2014). Beyond comfort, estrogen therapy slows bone mass loss after menopause and lowers fracture risk in postmenopausal women, a benefit strong enough that NAMS recommends hormone therapy specifically for osteoporosis prevention in appropriate candidates (NAMS, 2022; Stuenkel et al., 2015). Estradiol alone supports several hundred physiological functions tied to skeletal and dermatological health, including collagen maintenance and reduced skin thinning, while progesterone contributes bone-strengthening effects and helps regulate LDL cholesterol (Stuenkel et al., 2015). For athletes and physically active women, this bone-protective effect matters directly: stronger bone density supports training longevity and reduces stress fracture vulnerability during heavy conditioning cycles.

Cardiovascular health also factors into the benefit conversation, though carefully. HRT can help maintain cardiovascular function in women who initiate therapy before age 60 or within ten years of menopause onset, yet hormone therapy is not recommended solely for cardiovascular disease prevention (NAMS, 2022; Stuenkel et al., 2015). Timing genuinely changes the risk-benefit calculation; starting therapy earlier in the menopausal transition produces a more favorable safety profile than starting a decade or more after menopause begins (NAMS, 2022; ACOG, 2014). One striking data point from long-term Women’s Health Initiative follow-up: estrogen-only therapy in women with a prior hysterectomy was associated with a 23% decrease in breast cancer incidence, alongside lower breast cancer mortality compared to placebo (Chlebowski et al., as cited in AAFP, 2021). DHEA supplementation, when clinically indicated, supports downstream estrogen production as adrenal output naturally declines with age, contributing to secondary benefits in mood and skin quality (Stuenkel et al., 2015).

How Personalized Plans Get Built

Physicians build personalized HRT plans by reviewing medical history, family medical history, current hormone levels, and any prior diagnosis involving breast cancer, blood clots, liver disease, or gallbladder disease. A thorough health history intake typically covers cardiovascular disease markers, high blood pressure, prior heart attack, and any history of vaginal bleeding outside expected patterns. Physicians also consider whether early menopause has occurred, since younger women facing estrogen deficiency generally warrant longer treatment duration than those entering menopause at a typical age (NAMS, 2022). This individualized process explains why HRT protocols vary from one client to the next; no single universal dose or delivery method suits everyone equally.

Risks Every Candidate Should Understand

No responsible conversation about hormone therapy skips the risks. HRT can increase the risk of blood clots and stroke, with oral estrogen specifically raising venous thromboembolism risk more than transdermal forms (NAMS, 2022). Combined HRT increases breast cancer risk with long-term use, an association first surfaced by the Women’s Health Initiative and reinforced through subsequent follow-up analyses (Chlebowski et al., 2020, as cited in Manson et al., 2026). Following that 2002 finding, HRT initiation rates dropped sharply from 8.6% to 1.9%, a decline attributed directly to safety concerns raised by the Women’s Health Initiative data (NAMS, 2022).

Additional considerations include breast tenderness, mood swings, fluid retention, and weight gain, which some women experience during the adjustment period after starting therapy. Higher estrogen doses elevate heart attack risk in certain populations, which is precisely why physicians favor the lowest dose capable of managing symptoms rather than defaulting to higher amounts (NAMS, 2022). HRT is not appropriate for women with a documented history of certain cancers, active blood clots, unexplained vaginal bleeding, or liver disease, and careful monitoring alongside regular reassessments remains essential throughout treatment (NAMS, 2022). Research suggests that risk profiles shift meaningfully based on age, delivery method, and duration, which is why the Department of Health and Human Services and NAMS both emphasize individualized decision-making over blanket recommendations (U.S. Department of Health and Human Services, 2023; NAMS, 2022).

How Physician-Guided Care Works With TRT Colombia

Physician-guided hormone optimization in Colombia gives international clients access to licensed physicians and partner clinics without the extended waiting periods common in many home countries. TRT Colombia connects clients to trusted doctor-allies who conduct thorough medical history reviews, order relevant bloodwork, and design treatment plans aligned with international clinical standards, including guidance drawn from bodies such as the Menopause Society (NAMS, 2022). Every plan begins with a physician evaluation; qualified candidates then proceed toward a personalized regimen suited to their hormone needs and health profile, while treatment decisions rest entirely with the licensed physician overseeing care.

Transparent pricing sits alongside physician-guided care as a defining feature of the Colombia experience, rather than positioning Colombia purely as an inexpensive alternative. Clients receive detailed explanations of systemic therapy options, delivery methods such as skin patches or the vaginal ring, and honest discussion of risks including blood clots, breast cancer risk, and cardiovascular disease before any treatment begins. If medically appropriate, doctor-allies may recommend bioidentical hormones or FDA approved hormone therapy formulations tailored to symptom severity and personal risk tolerance.

Steps Involved in the Colombia Process

The coordination process generally follows several stages designed for clarity and safety. Initial intake collects health history, current symptoms, and prior lab results so doctor-allies can assess candidacy before travel arrangements begin. A licensed physician then reviews bloodwork and medical history remotely or in person, determining whether systemic hormone therapy, local estrogen therapy, or an alternative approach best matches the client’s presentation. Following physician approval, the partner clinic schedules the visit, coordinates any required monitoring, and establishes a follow-up schedule for ongoing reassessment, consistent with NAMS guidance recommending periodic evaluation throughout treatment (NAMS, 2022). Clients leave with a documented plan covering dosage, delivery method, and scheduled check-ins to track hormone levels and symptom response over time.

Making an Informed Decision

Deciding whether to pursue hormone replacement therapy involves weighing severe hot flashes, vaginal dryness, sleep disruption, and mood swings against personal risk factors like family medical history of breast cancer or clotting disorders. Women who continue hormone therapy under physician supervision typically see sustained relief from menopausal symptoms alongside protective effects against osteoporosis, provided monitoring continues as recommended (NAMS, 2022). Nobody should attempt to self-manage dosing or pursue compounded hormones without physician oversight, given the documented safety gaps in unregulated formulations (The Menopause Society, 2022).

Athletes and physically active women in particular stand to benefit from stabilized hormone levels, since estrogen deficiency affects bone density, recovery, and training capacity well past the commonly discussed symptoms. A conversation with a licensed physician, grounded in complete medical history and the current research, is the best starting point for anyone considering hormone therapy for menopause symptoms.

Frequently Asked Questions

Is hormone replacement therapy safe for everyone experiencing menopause symptoms?
No single treatment suits every candidate. Physicians assess personal and family medical history, current health conditions, and symptom severity before recommending systemic or local therapy.

What is the difference between estrogen only therapy and combined hormone therapy?
Estrogen only therapy suits women without a uterus, while combined hormone therapy adds progesterone to protect the uterine lining in women who still have one.

Can hormone therapy help with more than hot flashes?
Yes. Beyond relieving hot flashes and night sweats, therapy can slow bone loss, support vaginal health, and improve overall quality of life for many women.

How does Colombia’s process work for international clients?
Clients complete an intake and medical review with doctor-allies, receive physician evaluation, and follow a personalized plan coordinated through partner clinics with transparent pricing.

Is compounded hormone therapy the same as FDA approved hormone therapy?
No. Compounded formulations are custom-mixed without the same regulatory testing, while FDA-approved products undergo standardized safety and quality review.

References

American Academy of Family Physicians. (2021). Lower breast cancer mortality with estrogen alone, no significant change with estrogen plus progesterone. American Family Physician. https://www.aafp.org/pubs/afp/issues/2021/0115/od1.html

American College of Obstetricians and Gynecologists. (2014). ACOG Practice Bulletin No. 141: Management of menopausal symptoms. Obstetrics & Gynecology, 123(1), 202-216. https://pubmed.ncbi.nlm.nih.gov/24463691/

Manson, J. E., Crandall, C. J., Rossouw, J. E., et al. (2026). Then and now: What we have learned from the Women’s Health Initiative. The Journal of Clinical Endocrinology & Metabolism, 111(4), e974.

North American Menopause Society. (2022). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 29(7), 767-794. https://journals.lww.com/menopausejournal/fulltext/2022/07000/the_2022_hormone_therapy_position_statement_of_the.4.aspx

Stuenkel, C. A., Davis, S. R., Gompel, A., Lumsden, M. A., Murad, M. H., Pinkerton, J. V., & Santen, R. J. (2015). Treatment of symptoms of the menopause: An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 100(11), 3975-4011. https://www.endocrine.org/-/media/endocrine/files/cpg/menopause-cpg-resource-page-13feb18.pdf

The Menopause Society. (2022). 2022 Hormone Therapy Position Statement press release. https://menopause.org/wp-content/uploads/press-release/ht-position-statement-release.pdf

U.S. Department of Health and Human Services, Office on Women’s Health. (2023). Menopausal hormone therapy information.